A retrospective cohort study was conducted comparing the outcomes of patients with advanced PD‐L1(‐) nonsquamous NSCLC who were treated with antiangiogenic therapy plus chemotherapy (A Group) to those who were treated with anti‐PD‐L1 monoclonal antibodies plus chemotherapy (mAbs) (B Group). Here, CD274 is linked to non-small cell lung carcinoma.